Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02754596 · ClinicalTrials.gov registry record · Phase 2
Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic Solution
A Phase 2 study, sponsored by Glaukos Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 154
- Enrollment target
NCT02754596: Completed Phase 2 study, sponsored by Glaukos Corporation.
NCT02754596 is a Phase 2 study that has completed, run by Glaukos Corporation. The registered enrollment target is 154 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (16% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02754596, a Phase 2 study, has completed, sponsored by Glaukos Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 154 participants
- Enrollment target
Study Summary
This is a randomized trial comparing two elution doses of the Travoprost Intraocular implant to timolol ophthalmic solution.
Primary Outcome
Change from baseline in IOP (measured in mmHg) at week 12. Negative values represent reductions in IOP from baseline.
Interventions
- DRUG Timolol Maleate Ophthalmic Solution, 0.5%
- DRUG Travoprost Intraocular Implant, high elution
- DRUG Travoprost Intraocular Implant, low elution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2016-03-29 |
| Est. Completion | 2020-07-21 |
| Phase | Phase 2 |
What the finished NCT02754596 record still lists
NCT02754596 is an interventional study that assigns participants to a tested intervention. The registered 154 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (16% higher).
The record links to 0 conditions, and to 3 interventions - of which Timolol Maleate Ophthalmic Solution, 0.5% is the first listed.
NCT02754596 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02754596 about?
NCT02754596 is a clinical study titled "Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic Solution". This is a randomized trial comparing two elution doses of the Travoprost Intraocular implant to timolol ophthalmic solution.
What is the current status of trial NCT02754596?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 154 participants. The study started on 2016-03-29. Estimated completion is 2020-07-21.
What interventions are being tested in trial NCT02754596?
The interventions under investigation include: Timolol Maleate Ophthalmic Solution, 0.5% (DRUG), Travoprost Intraocular Implant, high elution (DRUG), Travoprost Intraocular Implant, low elution (DRUG).
Who is sponsoring clinical trial NCT02754596?
This trial is sponsored by Glaukos Corporation, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02754596's enrollment target sits among peer trials
154 448th of 2000 higher than 1,552 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04300998 · 154 participants
Study of CAR-T Therapy in Older Patients
- NCT04597372 · 154 participants · Phase 2
Impact of Tamsulosin on Post-Operative Urinary Retention Following Pelvic Reconstructive Surgery
- NCT05294042 · 154 participants · NA
Patient Navigators for Children's Community Mental Health Services in High Poverty Urban Communities
- NCT05512390 · 154 participants · Phase 1
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI